PPT-PCSK9 Inhibition: LDL Lowering

PCSK9 inhibitors New option for dyslipidemia Alireza EsteghamatiMD November 2018 Agenda Residual risk after Statin PCCSK9 Inhibitors physiology amp mechanism of action PCSK9 Inhibitor trials . 0. International Atherosclerosis Society, 2013. American Diabetes Association, 2013. European Atherosclerosis Society, 2013. European Society of Cardiology, 2012. National Heart, Lung, and Blood Institute & National Institutes of Health & American Academy of Pediatrics, 2011. of Cholesterol Metabolism:. The Role of . Proprotein. . Convertase. . Subtilisin. -like/. kexin. Type 9 (PCSK9) . in the Regulation of Low-Density Lipoprotein Cholesterol (LDL-C) and LDL . Receptors (LDL-Rs). Inhibition is a term used to describe the inability of a product being formed due to the presence of another substance (the inhibitor). Enzyme inhibition . can be competitive or noncompetitive. Competitive inhibition is caused when an inhibitor “competes” with the substrate in binding with the enzyme. Implications of the relationship between risk factor (LDL-C) level and event rate. Risk factor level. Risk factor level. LOG of. event. rate. Event . rate. 1: Is there a continuous relationship?. 2: Is there a lower limit?. CGR 0800 h 11 May 2015. Rob Hegele MD FRCPC FACP. Distinguished Professor of Medicine and Biochemistry. Western University. London, Canada. hegele@robarts.ca. Financial disclosure: speaker and ad board member for . Lowering Sodium without Losi ng Flavor Union Public Schools Tulsa, Oklahoma Lisa Griffin, RD, LD Callie Fowler- Farish Director of Child Nutrition District Executive Chef Union Public Schools-Tulsa, OK 2013 ACC/AHA Guideline on the. Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. IMPROVE-IT. 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia. Evolocumab. and Outcomes in Patients with . Peripheral Artery Disease. : Insights from the FOURIER Trial. Marc P. Bonaca, Patrice Nault, Robert P. Giugliano, Anthony C. . Keech. , Armando Lira Pineda, Estella Kanevsky, Julia Kuder, Sabina A. Murphy, J. . John Kastelein, MD . Academic Medical Centre. Amsterdam, The Netherlands. Slides. . prepared. and . presented. . by. At CV Risk . master. classes 2013. 2. Novel Approaches to Modify . Lipids and Lipoproteins. Evidence from . meta-analyses of . Mendelian. . randomization. studies. , . prospective. cohort studies. , . and. . randomized. . controlled. trials . unequivocally establishes that LDL causes ASCVD. . 4. th. Stage . Dr. Dalia . Abd. Al- Kader. PhD Pharmacology. Coronary heart disease . (CHD) . is correlated with elevated levels of low-density lipoprotein cholesterol (LDL-C; “bad” cholesterol) and triglycerides and low levels of high-density lipoprotein cholesterol (HDL-C; “good cholesterol”). . Assist.Lecturer. Aseel. . Ghassan. . Daoud. M.Sc. in Pharmacy/Clinical Laboratory Sciences. What are types of . lipopropteins. ?. There are 5 types from the largest to the smallest size:. Chylomicrones. Publication about . this. . research. : . Y. Zhang, M. . Ultsch. , N. Skelton, S. Burdick, M. . Beresini. , W. Li, M. Kong-Beltran, A. Peterson, J. Quinn, C. Chiu, Y. Wu, S. Shia, P. Moran, P. Di . Lello. DB09302. Description. :. Alirocumab. is a biopharmaceutical drug approved by the FDA in July 2015 as a second line treatment for high cholesterol for adults whose LDL-cholesterol (LDL-C) is not controlled by diet and statin treatment. It is a human monoclonal antibody administered by subcutaneous injection that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood.